Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Algernon NeuroScience
Deal Size : Undisclosed
Deal Type : Partnership
Algernon Appoints Validcare as CRO for DMT Stroke Trial, $170K Equity Investment
Details : The partnership aims to advance the clinical development of company's mid-stage product AP-188 (dimethyltryptamine). It is being evaluated for stroke and traumatic brain injury.
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 05, 2025
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Algernon NeuroScience
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?